dc.contributor.author | Jokinen, Elmeri M. | |
dc.contributor.author | Postila, Pekka A. | |
dc.contributor.author | Ahinko, Mira | |
dc.contributor.author | Niinivehmas, Sanna | |
dc.contributor.author | Pentikäinen, Olli T. | |
dc.date.accessioned | 2019-08-23T05:41:42Z | |
dc.date.available | 2019-08-23T05:41:42Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Jokinen, E. M., Postila, P. A., Ahinko, M., Niinivehmas, S., & Pentikäinen, O. T. (2019). Fragment‐ and Negative Image‐Based Screening of Phosphodiesterase 10A Inhibitors. <i>Chemical Biology and Drug Design</i>, <i>94</i>(4), 1799-1812. <a href="https://doi.org/10.1111/cbdd.13584" target="_blank">https://doi.org/10.1111/cbdd.13584</a> | |
dc.identifier.other | CONVID_31382011 | |
dc.identifier.uri | https://jyx.jyu.fi/handle/123456789/65279 | |
dc.description.abstract | A novel virtual screening methodology called fragment‐ and negative image‐based (F‐NiB) screening is introduced and tested experimentally using phosphodiesterase 10A (PDE10A) as a case study. Potent PDE10A‐specific small‐molecule inhibitors are actively sought after for their antipsychotic and neuroprotective effects. The F‐NiB combines features from both fragment‐based drug discovery and negative image‐based (NIB) screening methodologies to facilitate rational drug discovery. The selected structural parts of protein‐bound ligand(s) are seamlessly combined with the negative image of the target's ligand‐binding cavity. This cavity‐ and fragment‐based hybrid model, namely its shape and electrostatics, is used directly in the rigid docking of ab initio generated ligand 3D conformers. In total, 14 compounds were acquired using the F‐NiB methodology, 3D quantitative structure‐activity relationship modeling and pharmacophore modeling. Three of the small‐molecules inhibited PDE10A at ~27 μM to ~67 μM range in a radiometric assay. In a larger context, the study shows that the F‐NiB provides a flexible way to incorporate small‐molecule fragments into the drug discovery. | en |
dc.format.mimetype | application/pdf | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Wiley-Blackwell Publishing, Inc. | |
dc.relation.ispartofseries | Chemical Biology and Drug Design | |
dc.rights | In Copyright | |
dc.subject.other | skitsofrenia | |
dc.subject.other | Parkinsonin tauti | |
dc.subject.other | Huntingtonin tauti | |
dc.subject.other | lääkkeet | |
dc.subject.other | phosphodiesterase 10A (PDE10A) | |
dc.subject.other | schizophrenia | |
dc.subject.other | Parkinson’s disease | |
dc.subject.other | Huntington’s disease | |
dc.subject.other | negative image based (NIB) | |
dc.subject.other | fragment | |
dc.subject.other | negative image based (FNiB) screening | |
dc.subject.other | virtual screening | |
dc.subject.other | structure-based virtual screening | |
dc.subject.other | radiometric activity assay | |
dc.subject.other | fragment-based drug discovery | |
dc.title | Fragment‐ and Negative Image‐Based Screening of Phosphodiesterase 10A Inhibitors | |
dc.type | article | |
dc.identifier.urn | URN:NBN:fi:jyu-201908233880 | |
dc.contributor.laitos | Bio- ja ympäristötieteiden laitos | fi |
dc.contributor.laitos | Matemaattis-luonnontieteellinen tiedekunta | fi |
dc.contributor.laitos | Department of Biological and Environmental Science | en |
dc.contributor.laitos | Faculty of Mathematics and Science | en |
dc.contributor.oppiaine | Solu- ja molekyylibiologia | fi |
dc.contributor.oppiaine | Nanoscience Center | fi |
dc.contributor.oppiaine | Cell and Molecular Biology | en |
dc.contributor.oppiaine | Nanoscience Center | en |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | |
dc.description.reviewstatus | peerReviewed | |
dc.format.pagerange | 1799-1812 | |
dc.relation.issn | 1747-0277 | |
dc.relation.numberinseries | 4 | |
dc.relation.volume | 94 | |
dc.type.version | acceptedVersion | |
dc.rights.copyright | © 2019 John Wiley & Sons A/S | |
dc.rights.accesslevel | openAccess | fi |
dc.subject.yso | lääkkeet | |
dc.subject.yso | Huntingtonin tauti | |
dc.subject.yso | Parkinsonin tauti | |
dc.subject.yso | seulonta | |
dc.subject.yso | skitsofrenia | |
dc.format.content | fulltext | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p1077 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p18497 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p294 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p11811 | |
jyx.subject.uri | http://www.yso.fi/onto/yso/p9659 | |
dc.rights.url | http://rightsstatements.org/page/InC/1.0/?language=en | |
dc.relation.doi | 10.1111/cbdd.13584 | |
jyx.fundinginformation | The project was funded by the Jenny and Antti Wihuri Foundation (MA), the Emil Aaltonen Foundation (MA), the Finnish Cultural Foundation, Varsinais‐Suomi Regional fund (EMJ; 85182232), and the Academy of Finland (SN; 315492). CSC, The Finnish IT Centre for Science, is acknowledged for generous computational grants (O.T.P. projects jyy2516, jyy2585, and jyy2586). | |
dc.type.okm | A1 | |